Overview

PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function

Status:
Completed

Trial end date:
2009-07-01

Target enrollment:

Participant gender:

Summary

The study is being conducted to examine whether KW-3902IV will result in greater improvement in signs and symptoms of heart failure, with less treatment failure than standard therapy, when it is added to IV loop diuretics in subjects with acute heart failure syndrome and renal impairment.

Phase:

Phase 3

Details

Lead Sponsor:

NovaCardia, Inc.

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Diuretics
Purinergic P1 Receptor Antagonists
Rolofylline